GlassScriptPhysician profile
Lesley C Ballance
NPI 1033570015
$63,020.29
in general payments reported to CMS, 2019-2025
41 companies · $896 in 2025
The $896 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21K · 2022: $21K · 2023: $13K · 2024: $7,209 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $3,534 · Travel and Lodging: $3,331 · Consulting Fee: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,500.00 |
| Food and Beverage | $3,533.82 |
| Travel and Lodging | $3,330.70 |
| Consulting Fee | $562.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $42,382.55 | 2021-2025 | Calquence, Tagrisso, Enhertu |
| Abbvie INC. | $9,717.37 | 2021-2025 | |
| Seagen INC. | $1,820.83 | 2021-2023 | Padcev |
| Beigene, LTD. | $1,040.00 | 2021 | |
| Astrazeneca Uk Limited | $1,015.00 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $993.06 | 2022-2023 | Imbruvica |
| Genmab U.S., INC. | $953.19 | 2023-2025 | Epkinly |
| Janssen Biotech, INC. | $795.37 | 2021-2025 | Darzalex, Talvey, Rybrevant |
| Janssen Scientific Affairs, LLC | $782.42 | 2022-2023 | Imbruvica |
| Genentech, INC. | $750.00 | 2021 | |
| Adaptive Biotechnologies Corporation | $322.80 | 2021-2023 | Clonoseq |
| Celgene Corporation | $258.93 | 2022-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $256.34 | 2022-2025 | |
| Incyte Corporation | $171.35 | 2023-2025 | Jakafi, Monjuvi, Niktimvo |
| Beigene USA, INC. | $166.46 | 2022-2025 | Brukinsa |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $146.26 | 2022 | |
| Merck Sharp & Dohme LLC | $127.18 | 2023-2025 | Welireg, Keytruda, Reblozyl |
| Amgen INC. | $124.55 | 2022 | |
| Genzyme Corporation | $85.80 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $83.08 | 2024 | |
| Lilly USA, LLC | $81.36 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $78.33 | 2024-2025 | |
| Exelixis INC. | $76.37 | 2023-2025 | Cabometyx |
| Servier Pharmaceuticals LLC | $75.37 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.40 | 2022-2024 | Fruzaqla, Iclusig |
| Astellas Pharma US INC | $72.86 | 2023-2024 | Xospata, Cresemba |
| Regeneron Healthcare Solutions, INC. | $61.78 | 2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $58.16 | 2022-2023 | Rezlidhia, Tavalisse |
| Pharmaessentia USA Corporation | $56.49 | 2025 | Besremi |
| Eisai INC. | $51.80 | 2023-2025 | |
| Puma Biotechnology, INC. | $45.07 | 2025 | |
| Tersera Therapeutics LLC | $43.63 | 2025 | Zoladex |
| Legend Biotech USA INC. | $43.24 | 2025 | Carvykti |
| Jazz Pharmaceuticals INC. | $42.01 | 2023 | |
| Kyowa Kirin, INC. | $35.71 | 2022 | |
| Adc Therapeutics America, INC. | $28.84 | 2025 | |
| Agios Pharmaceuticals, INC. | $23.97 | 2025 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $21.35 | 2024 | Ultomiris |
| Emd Serono, INC. | $20.26 | 2025 | |
| Morphosys, US INC. | $19.81 | 2023 | Monjuvi |
| Taiho Oncology, INC. | $17.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Ballance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.